Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DMTPe
- Ownership
- Private
- Development stage
- Other
01
Overview
DMT Pharma (DMTPe) is an emerging biotechnology company focused on the development of novel psychedelic-based therapies for mental health disorders. The company specializes in optimizing the delivery and pharmacological profile of N,N-Dimethyltryptamine (DMT) and its analogs to treat conditions such as major depressive disorder and treatment-resistant depression. By leveraging advanced formulation techniques, DMTPe aims to provide rapid-acting therapeutic interventions with shorter duration profiles compared to traditional psychedelics. Their research is centered on targeting the 5-HT2A receptor to induce neuroplasticity and provide long-lasting symptomatic relief.
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on DMTPe.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DMTPe.